Chemotherapy Agents: A Primer for the Interventional Radiologist

ABSTRACT

In this article, the authors review the basic principles of cancer chemotherapy and provide an overview of each of the general classes of chemotherapeutic agents with a target audience of interventional radiologists in mind. Special attention is paid to agents used in regional chemotherapy as well as agents commonly included in systemic chemotherapeutic regimens for patients who also require regional chemotherapy.

KEYWORDS

Regional chemotherapy - principles of chemotherapy - cancer chemotherapy - chemotherapy review - chemotherapy agents

REFERENCES

• 1 Howard A, Pelc S R. Nuclear incorporation of P32 as demonstrated by autoradiographs.  Exp Cell Res. 1951;  2(2) 178-187
• 2 Reed S. Cell cycle. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 83
• 3 Lees J. Control of the cell cycle. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W Abeloff's Clinical Oncology. 4th ed. Philadelphia; Churchill Livingstone/Elsevier 2008: 50
• 4 Norton L. A Gompertzian model of human breast cancer growth.  Cancer Res. 1988;  48(24 Pt 1) 7067-7071
• 5 Goldie J H, Coldman A J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.  Cancer Treat Rep. 1979;  63(11-12) 1727-1733
• 6 Kinsella A R, Smith D. Tumor resistance to antimetabolites.  Gen Pharmacol. 1998;  30(5) 623-626
• 7 Ray C, Koczwara B. Principles of chemotherapy. In: Ray CE, Hicks ME, Patel NH Interventions in Oncology. Fairfax VA; Society of Interventional Radiology 2003: 9-15
• 8 Huitema A D, Smits K D, Mathôt R A, Schellens J H, Rodenhuis S, Beijnen J H. The clinical pharmacology of alkylating agents in high-dose chemotherapy.  Anticancer Drugs. 2000;  11(7) 515-533
• 9 Hirsch J. An anniversary for cancer chemotherapy.  JAMA. 2006;  296(12) 1518-1520
• 10 Kummar S, Noronha V, Chu E. Antimetabolites. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 358
• 11 Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs.  Br J Clin Pharmacol. 1999;  47(2) 131-143
• 12 Rowinsky E, Tolcher A. Antimicrotubule agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 390-411
• 13 Verstappen C C, Koeppen S, Heimans J J et al.. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.  Neurology. 2005;  64(6) 1076-1077
• 14 Takimoto C. Topoisomerase interactive agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 375-389
• 15 Colvin O, Friedman H. Alkylating agents. In: DeVita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 332-344
• 16 Copur M, Rose M, Chu E. Miscellaneous chemotherapeutic agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 417
• 17 Gately D P, Howell S B. Cellular accumulation of the anticancer agent cisplatin: a review.  Br J Cancer. 1993;  67(6) 1171-1176
• 18 Johnson S, O'Dwyer P. Cisplatin and its analogues. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 344-358
• 19 Ito Y, Sasaki Y, Horimoto M et al.. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.  Hepatology. 1998;  27(4) 951-958
• 20 Llovet J M, Ricci S, Mazzaferro V SHARP Investigators Study Group et al. Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359(4) 378-390
• 21 Sondak V, Redman B. Pharmacology of cancer biotherapeutics. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 423-430
• 22 Mier J, Atkins M. Interleukin-2. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 431-438
• 23 Marks P, Richon V, Miller T, Kelly W. Histone deacetylase inhibitors: new targeted anticancer drugs. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 439-445
• 24 Cheng J, Adams G, Robinson M, Weiner L. Monoclonal antibodies. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 445-456
• 25 Goetz M, Erlichman C, Loprinzi C. Pharmacology of endocrine manipulation. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 457-469